|Solubility||Soluble in DMSO.|
|Declaration||Manufactured by SynKinase.|
|Other Product Data||
Target: CHK1 | Kinase Group: CAMK | Substrate: Serine-Threonine
Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
CCT244747 is a novel, potent, highly selective, orally active, ATP competitive CHK1 inhibitor. CCT244747 can inhibit cellular CHK1 activity with an IC50 of 29-170nM. In multiple tumour cell models, this has the effect of significantly enhancing the cytotoxicity of several anticancer drugs (such as gemcitabine and irinotecan) and abrogating drug-induced S and G2 arrest.
- Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors: M. Lainchbury, et al.; J. Med. Chem. 55, 10229 (2012)
- CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs: M.I. Walton, et al.; Clin. Cancer Res. 18, 5650 (2012)
- The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment: I. Patties, et al.; J. Exp. Clin. Cancer Res. 38, 420 (2019)